The FDA May Approve 'Mix-and-Match' Booster Shots as Soon as This Week -- Barrons.com
The FDA May Approve 'Mix-and-Match' Booster Shots as Soon as This Week -- Barrons.com
By Jack Denton
杰克·丹顿(Jack Denton)著
U.S. residents ready for a Covid-19 booster shot may be able to get a different type of vaccine than the dose they initially received.
准备接种新冠肺炎强化注射的美国居民可能会获得与他们最初接种的疫苗不同类型的疫苗。
The Food and Drug Administration is moving to allow people to take a "mix-and-match" approach to vaccine boosters as soon as this week, according to reports from The Wall Street Journal and the New York Times that cited anonymous sources.
据“华尔街日报”和“纽约时报”援引匿名消息人士的话报道，美国食品和药物管理局(Food and Drug Administration，简称FDA)正采取行动，允许人们最早在本周采取“混合搭配”的方式接种疫苗。
People can currently only receive a booster dose of the same vaccine they initially received. Last Friday, members of the FDA's vaccines advisory committee signaled a readiness to authorize mixed boosters.
人们目前只能接种与最初接种的疫苗相同的加强剂量。上周五，FDA疫苗咨询委员会的成员表示愿意授权混合佐剂。
The FDA won't recommend any one booster over another but will allow people to get a different dose than from their initial vaccination program, the reports said. The regulator may note that using the same vaccine as a booster is preferable when possible, according to the Times, which earlier reported the news.
报道称，FDA不会推荐任何一种增强剂而不是另一种，但将允许人们获得与最初疫苗接种计划不同的剂量。据早些时候报道这一消息的泰晤士报报道，监管机构可能会注意到，在可能的情况下，使用相同的疫苗作为增强剂是更可取的。
Also read: FDA Vaccines Committee Seems Open to Mix-and-Match Boosters. What That Could Look Like.
另请阅读：FDA疫苗委员会似乎对混合配对推动者持开放态度。那会是什么样子。
The Journal report added that the FDA was on track to authorize the vaccines from Moderna (ticker: MRNA) and Johnson & Johnson (JNJ) as booster shots this week.
“华尔街日报”的报道补充说，美国食品药品监督管理局(FDA)将在本周授权摩德纳(股票代码：mRNA)和强生(JNJ)的疫苗作为增强疫苗。
The regulator has already authorized booster shots of the vaccine from Pfizer (PFE) and its partner BioNTech (BNTX) for seniors and people at high risk of severe illness, as well as for those with compromised immune systems. The shot from Moderna has similarly been greenlit for immunocompromised people.
监管机构已经授权辉瑞(Pfizer)及其合作伙伴BioNTech(BNTX)为老年人和严重疾病高危人群以及免疫系统受损的人注射疫苗。来自莫德纳的疫苗同样也为免疫受损的人开了绿灯。
Allowing a mix-and-match approach has been touted by some health experts and authorities as a way to simplify the logistics of a booster shot rollout. It could also change the dynamics of the vaccine market.
一些健康专家和当局一直吹捧允许混合匹配的方法，认为这是一种简化助推器注射推出的后勤工作的方式。它还可能改变疫苗市场的动态。
As Barron's Josh Nathan-Kazis wrote last week, "data on the safety and efficacy of mix-and-match boosting will eventually determine how much room there is for other players in the Covid-19 vaccine market." If mix-and-match boosters are widely approved, it bodes well for the makers of Covid-19 vaccines still under development, such as Sanofi (SNY), Novavax (NVAX), and CureVac (CVAC).
正如巴伦公司的乔什·内森-卡齐斯上周所写的那样，“关于混合配型疫苗的安全性和有效性的数据最终将决定新冠肺炎疫苗市场上其他参与者还有多大的空间。”如果混合配伍疫苗获得广泛认可，对仍在研发中的新冠肺炎疫苗生产商来说是个好兆头，比如赛诺菲(Sanofi)、诺华(Novavax)和氯氟乙烯(CureVac)。
Write to Jack Denton at jack.denton@dowjones.com
写信给杰克·丹顿(Jack Denton)，电子邮件：jack.denton@dowjones.com